Spots Global Cancer Trial Database for lymphoid malignancy
Every month we try and update this database with for lymphoid malignancy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer | NCT00982566 | Lymphoid Malign... Solid Tumors | ABT-263 ABT-263 ABT-263 ABT-263 | 18 Years - | AbbVie | |
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | NCT00048737 | Lymphoma Leukemia | Zevalin Radioim... Rituximab Fludarabine Cyclophosphamid... Allogeneic Stem... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | NCT00001830 | Chronic Lymphoc... Graft vs Host D... Hodgkin's Disea... Multiple Myelom... Non Hodgkin's L... | Th2 cells in al... Th2 Cells | 12 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies | NCT00820508 | Hematological D... Lymphoid Malign... | CHR-2845 | 18 Years - | Chroma Therapeutics | |
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | NCT00001830 | Chronic Lymphoc... Graft vs Host D... Hodgkin's Disea... Multiple Myelom... Non Hodgkin's L... | Th2 cells in al... Th2 Cells | 12 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | NCT03759184 | Leukemia Lymphocytic Chronic B-Cell | rhIL-15 rhIL-15 Obinutuzumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | NCT03759184 | Leukemia Lymphocytic Chronic B-Cell | rhIL-15 rhIL-15 Obinutuzumab | 18 Years - | National Institutes of Health Clinical Center (CC) |